Chronic lithium administration triggers an over-expression of GRP94 stress protein isoforms in mouse liver

Food and Chemical Toxicology

Volumn 48, Issue 6, 2010, Pages 1638-1643

  Nciri, R ^a,b   Allagui, M S ^a,b   Vincent, C ^b   Murat, J C ^b   Croute, F ^b   Feki, A El ^a  

^a University of Sfax   (Tunisia)

^b UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

GRP; HSP; Lithium; Liver; Mouse; TBARS

Indexed keywords

CATALASE; CREATININE; GLUCOSE REGULATED PROTEIN 94; GLUTATHIONE PEROXIDASE; HEAT SHOCK PROTEIN 72; HEAT SHOCK PROTEIN 73; LIPID; LITHIUM CARBONATE; PROTEIN ANTIBODY; SUPEROXIDE DISMUTASE; UREA;

ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; KIDNEY; LIPID PEROXIDATION; LIVER; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN PHOSPHORYLATION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; CREATININE; LIPID PEROXIDATION; LITHIUM COMPOUNDS; LIVER; MALE; MEMBRANE GLYCOPROTEINS; MICE; PROTEIN ISOFORMS; UREA;

MUS;

EID: 77952880078     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fct.2010.03.038     Document Type: Article

References (52)

1. Adityanjee K.R., Munshi A.T. The syndrome of irreversible lithium-effectuated neurotoxicity. Clin. Neuropharmacol. 2005, 28:38-49.
2. Aebi H. Catalase in vitro. Meth. Enzymol. 1984, 105:121-126.
3. Agneta Nilsson M.D., Rolf Axelsson M.D. On the elimination half-life of lithium in long-term treatment of patients with affective disorders human psychopharmacology: clinical and. Experimental 2004, 4:247-257.
4. Allagui M.S., Nciri R., Rouhaud M.F., Murat J.C., El Feki A., Croute F., Vincent C. Long-term exposure to low lithium concentrations stimulates proliferation, modifies stress protein expression pattern and enhances resistance to oxidative stress in SH-SY5Y cells. Neurochem. Res. 2009, 34(3):453-462.
5. Allagui, M.S., 2006. Effets cytotoxiques du lithium, in vivo chez le rat pubère, et in vitro sur des lignées cellulaires humaines. Étude du stress oxydant et de l'expression des protéines de stress. Essai d'évaluation des effets neuroprotecteurs du lithium. Doctoral Thesis, Sfax University, Tunisia.
6. Allagui M.S., Vincent C., Elfeki A., Gaubin Y., Croute F. Lithium toxicity and expression of stress-related genes or proteins in A549 cells. Biochim. Biophys. Acta 2007, 1773(7):1107-1507.
7. Altmeyer A., Maki R.G., Feldweg A.M., Heike M., Protopopov V.P., Masur S.K., Srivastava P.K. Tumor-specific cell surface expression of the KDEL containing, endoplasmic reticular heat shock protein gp96. Int. J. Cancer Suppl. 1996, 69(4):340-349.
8. Ana Paula S.V., Fabiane A.N., Leonardo M.C., Luisa A.D., Lucia M.A., Martha E.P., Elizabete R.R., Carla D. Chronic lithium treatment has antioxidant properties but does not prevent oxidative damage induced by chronic variate stress. Neurochem. Res. 2006, 31:1141-1151.
9. Bando Y., Katayama T., Aleshin A.N., Manabe T., Tohyama M. GRP94 reduces cell death in SH-SY5Y cells perturbated calcium homeostasis. Apoptosis 2004, 9:501-508.
10. Bando Y., Katayama T., Kasai K., Taniguchi M., Tamatani M., Tohyama M. GRP94 (94kDa glucose-regulated protein) suppresses ischemic neuronal cell death against ischemia/reperfusion injury. Eur. J. Neurosci. 2003, 18:829-840.
11. Bearden C.E., Thompson P.M., Dalwani M., Hayashi K.M., Lee A.D., Nicoletti M. Greater cortical gray matter density in lithium-treated patients with bipolar disorder. Biol. Psychiatry 2007, 62:7-16.
12. Birch N.J., Grof P., Hullin R.P., Keheo R.F., Shcou M., Srinivasan D.P. Lithium prophylaxis: proposed guide-lines for good clinical practice. Lithium 1993, 4:225-230.
13. Bocchetta A., Bernardi F., Pedditzi M., Loviselli A., Velluzzi F., Martino E., Del Zompo M. Thyroid abnormalities during lithium treatment. Acta Psychiatr. Scand. 1991, 83:193-198.
14. Brostrom, C.O., Brostrom, M.A., 1998. Regulation of translational initiation during cellular responses to stress. Progress in nucleic acid research and molecular biology, vol. 58. Academic, San Diego, pp. 79-125.
15. Cala S.E. GRP94 hyperglycosylation and phosphorylation in Sf21 cells. Biochim. Biophys. Acta 2000, 1496(2-3):296-310.
16. Chuang D.M. Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases. Crit. Rev. Neurobiol. 2004, 16:83-90.
17. Croute F., Beau B., Murat J.C., Vincent C., Komatsu H., Obata F., Soleilhavoup J.P. Expression of stress-related genes in a cadmium-resistant A549 human cell-line. J. Toxicol. Environ. Health 2005, 68:703-718.
18. Cui J., Shao L., Young L.T., Wang J.F. Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience 2007, 23:1447-1453.
19. Cui J., Shao L., Young L.T., Wang J.F. Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience 2007, 23:1447-1453.
20. Dixon J.F., Hokin L.E. Lithium acutely inhibits and chronically up-regulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex. Proc. Natl. Acad. Sci. 1998, 95:8363-8368.
21. Durak I., Yurtarslanl Z., Canbolat O., Akyol O. A methodological approach to superoxide-dismutase (SOD) activity assay based on inhibition of nitroblue tetazolium (NBT) reduction. Clin. Chim. Acta 1993, 214:103-104.
22. Esterbauer H. Cytotoxicity and genotoxicity of lipid-oxidation products. Am. J. Clin. Nutr. 1993, 57(5):779-785.
23. Flohe L., Gunzler W.A. Assays of glutathione peroxidise. Methods Enzymol. 1984, 105:114-121.
24. Frasson M., Vitadello M., Brunati A.M., La Rocca N., Tibaldi E., Pinna L.A., Gorza L., Donella-Deana A. Grp94 is Tyr-phosphorylated by Fyn in the lumen of the endoplasmic reticulum and translocates to Golgi in differentiating myoblasts. Biochim. Biophys. Acta 2009, 1793(2):239-252.
25. Frey B.N., Valvassori S.S., Reus G.Z., Martins M.R., Petronilho F.C., Bardini K., Dal-Pizzol F., Kapczinski F., Quevedo J. Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J. Psychiatry. Neurosci. 2006, 31:326-332.
26. He L., Fox M.H. Variation of heat shock protein 70 through the cell cycle in HL-60 cells and its relationship to apoptosis. Exp. Cell. Res. 1997, 232:64-71.
27. Kitamura Y., Nomura Y. Stress proteins and glial functions: possible therapeutic targets for neurodegenerative disorders. Pharmacol. Ther. 2003, 97:35-53.
28. Lai J.S., Zhao C., Warsh J.J., Li P.P. Cytoprotection by lithium and valproate varies between cell types and cellular stresses. Eur. J. Pharmacol. 2006, 539:18-26.
29. Lazarus J.H. The effects of lithium therapy on thyroid and thyrotropin-releasing hormone. Thyroid 1998, 8:909-913.
30. Liu H., Lightfoot R., Stevens J.L. Activation of heat shock factor by alkylating agents is triggered by glutathione depletion and oxidation of protein thiols. J. Biol. Chem. 1996, 271:4805-4812.
31. Lowry O.H., Rosebrouch N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
32. Manji H.K., Moore G.J., Chen G. Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. J. Clin. Psychiatry. 2000, 61(9):82-96.
33. Manji H.K., Moore G.J., Chen G. Lithium at 50: have the neuroprotective effects of this unique cation been over looked. Biol. Psychiatry 1999, 46:929-940.
34. Morimoto R.I., Kroeger P.E., Cotto J.J. The transcriptional regulation of heat shock genes: a plethora of heat shock factors and regulatory conditions. Stress-Inducible Cellular Responses 1996, 139-163. Birkhauser-Verlag, Basel. U. Feige, I. Moritimo, I. Yahara, B.S. Polla (Eds.).
35. Nciri R., Allagui M.S., Croute F., Vincent C., Elfeki A. Effets chroniques de faibles doses de carbonate de lithium chez la souris. Relations entre statut oxydant et modifications fonctionnelles et structurales des reins et du cerveau. C.R. Biologies 2008, 331:23-31.
36. Nciri R., Allagui M.S., Vincent C., Croute F., Elfeki A. The effects of subchronic lithium administration in male Wistar mice on some biochemical parameters. Hum. Exp. Toxicol. 2009, 28(10):641-646.
37. Nigam S.K., Goldberg A.L., Ho S., Ghode M.F., Bush K.T., Sherman M.Y.U. A set of endoplasmic reticulum proteins possessing properties of molecular chaperones includes CA2C binding proteins and member of the thioredoxin superfamily. J. Biol. Chem. 1994, 269:1744-1749.
38. Oktem F., Ozguner F., Sulak O., Olgar S., Akturk O., Yilmaz H.R., Altuntas I. Lithium induced renal toxicity in rats: protection by a novel antioxidant caffeic acid phenethyl ester. Mol. Cell. Biochem. 2005, 277:109-115.
39. 2+-binding and antiapoptotic properties is a novel proteolytic target of calpain during etoposide-induced apoptosis. J. Biol. Chem. 1999, 274(40):28476-28483.
40. Sassi R.B., Nicoletti M., Brambilla P., Mallinger A.G., Frank E., Kupfer D.J. Increased gray matter volume in lithium-treated bipolar disorder patients. Neurosci. Lett. 2002, 329:243-245.
41. Shaldubina A., Agam G., Belmaker V. The mechanism of lithium action: state of the art, ten years later. Prog. Neuropsychopharmacol. Biol. Psychiatry 2001, 25:855-866.
42. Shao L., Sun X., Xu L., Young L.T., Wang J.F. Mood stabilizing drug lithium increases expression of endoplasmic reticulum stress proteins in primary cultured rat cerebral cortical cells. Life Sci. 2006, 78:1317-1323.
43. Shao L., Young L.T., Wang J.F. Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biol. Psychiatry 2005, 58:879-884.
44. Smith R.C., Rosen K.M., Pola R., Magrane J. Stress proteins in Alzheimer's disease. Int. J. Hyperthermia 2005, 21:421-431.
45. Sun Y., Oberley L.W., Li Y. A simple method for clinical assay of superoxide-dismutase. Clin. Chem. 1988, 34:497-500.
46. Tam V.K., Green J., Schwieger J., Cohen A.H. Nephrotic syndrome and renal insufficiency associated with lithium therapy. Am. J. Kidney Dis. 1996, 27:715-720.
47. Turan T., Esel E., Tokgoz B., Aslan S., Sofuoglu S., Utas C., Kelestimur F. Effects of short- and long-term lithium treatment on kidney functioning in patients with bipolar mood disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26:561-565.
48. Wada A., Yokoo H., Yanagita T., Kobayashi H. Lithium: potential therapeutics against acute brain injuries and chronic neurodegenerative diseases. J. Pharmacol. Sci. 2005, 99(4):307-321.
49. Wang J.F., Shao L., Sun X., Young L.T. Glutathione S-transferase is a novel target for mood stabilizing drugs in primary cultured neurons. J. Neurochem. 2004, 88:1477-1484.
50. Wearsch A., Nicchitta C.V. Purification and partial molecular characterization of GRP94, an ER resident chaperone. Protein. Expr. Purif. 1996, 7(1):114-121.
51. Wood A.J., Goodwin G.M., Sousa R.D., Green A.R. The pharmacokinetic profile of lithium in rat and mouse; an important factor in psychopharmacological investigation of the drug. Neuropharmacology 1986, 25:1285-1288.
52. Wraae O. The pharmacokinetics of lithium in the brain, cerebrospinal fluid and serum of the rat. Br. J. Pharmacol. 1978, 64:273-279.